FDA extends review period for Humacyte’s vascular trauma treatment ATEV
The U.S. Food and Drug Administration’s review of Humacyte, Inc.’s innovative vascular trauma treatment, known as the acellular tissue engineered vessel (ATEV), has hit an unexpected delay, causing concern and curiosity in the medical and investment communities. Originally slated for completion by August 10, 2024, the FDA has not specified a new review completion date, […]